Cellular and molecular biology of small cell lung cancer: an overview.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Translational Lung Cancer Research

• Publication date

  2016-02-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3978/j.issn.2218-6751.2016.01.02PMID 26958489PMCID PMC4758976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stem Cells in Lung Cancer

  2019cited by this paper
• Cancer Immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

  2016cited by this paper
• DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2

  2015cited by this paper
• Novel therapies in small cell lung cancer.

  2015cited by this paper
• Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer

  2015cited by this paper
• A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells

  2015cited by this paper
• Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

  2015cited by this paper
• O-Fucosylation of DLL3 Is Required for Its Function during Somitogenesis

  2015cited by this paper
• A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).

  2015cited by this paper
• Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer

  2015cited by this paper
• NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas

  2015cited by this paper
• Cell-of-origin chromatin organization shapes the mutational landscape of cancer

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• Comprehensive genomic profiles of small cell lung cancer

  2015influential reference
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Abstract 1525: FAK and PI3K/mTOR inhibitors target cancer stem cells: Implications for SCLC treatment strategies

  2015cited by this paper
• PD-L1 expression in small cell neuroendocrine carcinomas.

  2015cited by this paper
• Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids

  2014cited by this paper
• 1229PDSMOKING HISTORY AND RESPONSE TO NIVOLUMAB IN PATIENTS WITH ADVANCED NSCLCS.

  2014cited by this paper
• RET mutations in neuroendocrine tumors: including small-cell lung cancer.

  2014cited by this paper
• From fly wings to targeted cancer therapies: a centennial for notch signaling.

  2014cited by this paper
• Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer

  2014cited by this paper
• Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer

  2014cited by this paper
• Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

  2014influential reference
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers

  2014influential reference
• EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer.

  2014cited by this paper
• Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.

  2014cited by this paper
• Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis

  2014cited by this paper
• CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.

  2014cited by this paper
• Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

  2013cited by this paper
• Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide

  2013cited by this paper
• NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM

  2013cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

  2013cited by this paper
• Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.

  2013cited by this paper
• Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPO-I, TOPO-iia, TOPO-iib, and c-MYC genes in patients with small cell lung cancer (SCLC) who received first-line therapy with cisplatin and etoposide.

  2013cited by this paper
• EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation

  2013cited by this paper
• NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition

  2013cited by this paper
• Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.

  2013cited by this paper
• Mouse models for lung cancer

  2013cited by this paper
• Notch inhibitors for cancer treatment.

  2013cited by this paper
• Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer

  2013cited by this paper
• A Genomics-Based Classification of Human Lung Tumors

  2013cited by this paper
• Cell of origin of lung cancer

  2013cited by this paper
• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

  2012cited by this paper
• Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

  2012cited by this paper
• Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway

  2012cited by this paper
• The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

  2012cited by this paper
• Multidirectional differentiation of Achaete-Scute homologue-1-defined progenitors in lung development and injury repair.

  2012cited by this paper
• Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis

  2012cited by this paper
• Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

  2012cited by this paper
• Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas

  2012cited by this paper
• Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

  2012cited by this paper
• Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

  2012cited by this paper
• A genetic snapshot of small cell lung cancer.

  2012cited by this paper
• Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.

  2011cited by this paper
• Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

  2011cited by this paper
• Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Nuclear factor I/B is an oncogene in small cell lung cancer.

  2011cited by this paper
• Characterization of the cell of origin for small cell lung cancer

  2011cited by this paper
• A crucial requirement for Hedgehog signaling in small cell lung cancer

  2011cited by this paper
• Neuroendocrine tumors of the lung: an update.

  2010cited by this paper
• Cell of origin of lung cancer

  2010cited by this paper
• ERCC1 and Ki67 in Small Cell Lung Carcinoma and Other Neuroendocrine Tumors of the Lung: Distribution and Impact on Survival

  2010cited by this paper
• Advances in neuroendocrine lung tumors.

  2010cited by this paper
• CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

  2009cited by this paper
• A small cell lung cancer genome reports complex tobacco exposure signatures

  2009cited by this paper
• Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.

  2009cited by this paper
• CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

  2009cited by this paper
• Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube.

  2009influential reference
• Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells

  2009cited by this paper
• Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.

  2009cited by this paper
• Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage

  2008cited by this paper
• Reciprocal CD4 T-Cell Balance of Effector CD62L CD4 and CD62LCD25 CD4 Regulatory TCells in Small Cell Lung Cancer Reflects Disease Stage

  2008cited by this paper
• Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer

  2008cited by this paper
• Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors.

  2007cited by this paper
• Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo

  2007cited by this paper
• Targeting the neural cell adhesion molecule in cancer.

  2007cited by this paper
• Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer.

  2007cited by this paper
• FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.

  2006cited by this paper
• Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

  2006cited by this paper
• Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis

  2006cited by this paper
• Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.

  2005cited by this paper
• Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

  2005cited by this paper
• Direct interactions among Ret, GDNF and GFRalpha1 molecules reveal new insights into the assembly of a functional three-protein complex.

  2005cited by this paper
• Identification of bronchioalveolar stem cells in normal lung and lung cancer.

  2005cited by this paper
• Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin

  2004cited by this paper
• Pathology & Genetics Tumours of the lung, Pleura, Thymus and Heart

  2004influential reference
• Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium.

  2004cited by this paper
• Stem cells in lung biology.

  2004cited by this paper
• Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles.

  2004cited by this paper
• Achaete-scute homolog-1 and Notch in lung neuroendocrine development and cancer.

  2004cited by this paper
• Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.

  2003influential reference
• The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung.

  2003cited by this paper
• Paraneoplastic syndromes involving the nervous system.

  2003cited by this paper

• Prognostic value of baseline LIPI, LDH and dNLR in ES-SCLC patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis

  2025cites this paper
• Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas

  2025cites this paper
• Exploring the Role of Peritumoral Edema in Predicting Lung Cancer Subtypes Through T2-FLAIR Digital Subtraction Imaging of Metastatic Brain Tumors

  2025cites this paper
• Biomarkers in lung cancer treatment.

  2025cites this paper
• Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics

  2025cites this paper
• The nuclear-cytoplasmic ratio controls the cell cycle period in compartmentalized frog egg extract

  2025cites this paper
• Histology-Specific Treatment Strategies and Survival Prediction in Lung Cancer Patients with Spinal Metastases: A Nationwide Analysis

  2025cites this paper
• Epidermal growth factor stimulates STAT5 via EGFR to promote lung adenocarcinoma growth

  2025cites this paper
• Expanding the immunotherapy universe in extensive-stage small cell lung cancer: from chemoimmunotherapy backbone to next-wave combinations

  2025cites this paper
• Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry

  2024influential citation
• Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer

  2024cites this paper
• Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study

  2024cites this paper
• C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer

  2024cites this paper
• Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure

  2024cites this paper
• Activating Invasion and Metastasis in Small Cell Lung Cancer: Role of the Tumour Immune Microenvironment and Mechanisms of Vasculogenesis, Epithelial‐Mesenchymal Transition, Cell Migration, and Organ Tropism

  2024cites this paper
• Cytomorphologic analysis of pulmonary neuroendocrine tumors - The physical effect of abrasion and aspiration on cytomorphology.

  2024cites this paper
• 小细胞肺癌分子分型：向临床实践转化的挑战

  2024influential citation
• Expression profiling of circulating lncRNA GIAT4RA, lncRNA AATBC, lncRNA Sirt1-AS, and SMARCB1 in lung cancer patients

  2024cites this paper
• Stimulation of cGAS-STING pathway as a challenge in the treatment of small cell lung cancer: a feasible strategy?

  2024cites this paper
• Immunotherapy for small cell lung cancer: the current state and future trajectories

  2024cites this paper
• Yolk-Shell Hierarchical Pore Au@MOF Nanostructures: Efficient Gas Capture and Enrichment for Advanced Breath Analysis.

  2024cites this paper
• An immune checkpoint-based signature predicts prognosis and chemotherapy response for patients with small cell lung cancer.

  2023cites this paper
• Sexual dimorphism in chronic respiratory diseases

  2023cites this paper
• A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer

  2023cites this paper
• Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer

  2023cites this paper
• Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer

  2022cites this paper
• Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer

  2022cites this paper
• Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines

  2022cites this paper
• The Nuclear-to-Cytoplasmic Ratio: Coupling DNA Content to Cell Size, Cell Cycle, and Biosynthetic Capacity.

  2022cites this paper
• Molecular Mechanisms Underlying the Development of Neuroendocrine Prostate Cancer.

  2022cites this paper
• Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer

  2022cites this paper
• Prognostic biomarkers and immune cell infiltration characteristics in small cell lung cancer

  2022influential citation
• Ferroptosis-associated gene SLC7A11 is upregulated in NSCLC and correlated with patient’s poor prognosis: An integrated bioinformatics analysis

  2021cites this paper
• Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC

  2021cites this paper
• Detection Of Lung Cancer On Computed Tomography Using Artificial Intelligence Applications Developed By Deep Learning Methods And The Contribution Of Deep Learning To The Classification Of Lung Carcinoma.

  2021cites this paper
• Neuron specific enolase promotes tumor metastasis by activating the Wnt/β-catenin pathway in small cell lung cancer

  2021cites this paper
• History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature

  2021cites this paper
• Molecular profiles of small cell lung cancer subtypes: therapeutic implications

  2021cites this paper
• Needle Trap Device-GC-MS for Characterization of Lung Diseases Based on Breath VOC Profiles

  2021cites this paper
• Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

  2021cites this paper
• Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry

  2021cites this paper
• The Past, Present, and Future (Liquid Biopsy) of Serum Tumor Markers in Lung Cancer: A Primer for the Radiologist

  2021cites this paper
• Small cell carcinoma of the brain without apparent extracranial origin in the same intracranial region one year following resection of malignant glioma.

  2021cites this paper
• Development of chemokine CXCL12-dependent immunotoxin against small cell lung cancer using in silico approaches

  2021cites this paper
• Response to first- line treatment predicts progression- free survival benefit of small- cell lung cancer patients treated with anlotinib

  2021cites this paper
• MUC1 and CD147 Are Promising Markers for the Detection of Circulating Tumor Cells in Small Cell Lung Cancer

  2021cites this paper
• Natural compound library screening identifies Sanguinarine chloride for the treatment of SCLC by upregulating CDKN1A

  2021cites this paper
• Neuron Speci c Enolase Promotes Metastasis by Activating the Wnt/β-catenin Pathway in Small Cell Lung Cancer

  2020cites this paper
• Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer.

  2020cites this paper
• A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy

  2020cites this paper
• Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach

  2020cites this paper
• Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer

  2020cites this paper
• Recent advances in small cell lung cancer: the future is now?

  2020cites this paper
• Lead DEAD/H box helicase biomarkers with the therapeutic potential identified by integrated bioinformatic approaches in lung cancer

  2020cites this paper
• Identification and validation of aberrant regulation of miR-445-3p /TTK , miR-140-5p/TTK and miR-133b/CDCA8 in small-cell lung cancer via bioinformatics analysis

  2020cites this paper
• Soluble fms‐like tyrosine kinase‐1‐enriched exosomes suppress the growth of small cell lung cancer by inhibiting endothelial cell migration

  2019cites this paper
• Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis

  2019cites this paper
• Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-gene pairs in small-cell lung cancer

  2019cites this paper
• Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications

  2019cites this paper
• OTT_A_216362 10043..10055

  2019cites this paper
• Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer

  2019cites this paper
• Mutation and immune profiling of non-small cell lung cancer

  2019cites this paper
• Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines

  2019cites this paper
• Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

  2019cites this paper
• MicroRNA‐26b suppresses tumorigenicity and promotes apoptosis in small cell lung cancer cells by targeting myeloid cell leukemia 1 protein

  2018influential citation
• Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis

  2018cites this paper
• Advanced small cell lung cancer (SCLC): new challenges and new expectations.

  2018cites this paper
• Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer

  2018cites this paper
• Deciphering structural stability and binding mechanisms of potential antagonists with smoothened protein

  2018cites this paper
• Pulmonary Malignancies (1): Lung Cancer—What Are the Roles of Genetic Factors in Lung Cancer Pathogenesis?

  2018cites this paper
• Molecular genetics of lung cancer

  2018cites this paper
• Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.

  2018cites this paper
• Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.

  2018cites this paper
• Progress and prospects of early detection in lung cancer

  2017cites this paper
• Significantly mutated genes and regulatory pathways in SCLC-a meta-analysis.

  2017cites this paper
• A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy

  2017cites this paper
• Immunotherapy for small-cell lung cancer: rationale and clinical evidence

  2017cites this paper
• Small Cell Lung cancer: Molecular Oncology Approach

  2017cites this paper
• Carboplatin and Etoposide With or Without Palifosfamide in Untreated Extensive-Stage Small-Cell Lung Cancer: A Multicenter, Adaptive, Randomized Phase III Study (MATISSE).

  2017cites this paper
• Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis

  2017cites this paper
• Combination chemotherapy for relapsed small-cell lung cancer—perspective on mechanisms of chemoresistance

  2016cites this paper
• Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.

  2016cites this paper
• Unraveling the genomic complexity of small cell lung cancer.

  2016cites this paper
• Improving the diagnostic armamentarium of lung cancer

  year unknowncites this paper